14.27
price up icon5.16%   0.70
pre-market  Vorhandelsmarkt:  14.02   -0.25   -1.75%
loading
Schlusskurs vom Vortag:
$13.57
Offen:
$13.95
24-Stunden-Volumen:
515.64K
Relative Volume:
0.76
Marktkapitalisierung:
$779.10M
Einnahmen:
$8.78M
Nettoeinkommen (Verlust:
$-104.70M
KGV:
-6.0211
EPS:
-2.37
Netto-Cashflow:
$-82.68M
1W Leistung:
+19.92%
1M Leistung:
+23.12%
6M Leistung:
+34.62%
1J Leistung:
-2.13%
1-Tages-Spanne:
Value
$13.92
$14.41
1-Wochen-Bereich:
Value
$11.89
$14.78
52-Wochen-Spanne:
Value
$5.35
$16.15

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name
Firmenname
Stoke Therapeutics Inc
Name
Telefon
781-430-8200
Name
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Name
Mitarbeiter
128
Name
Twitter
@stoketx
Name
Nächster Verdiensttermin
2025-03-18
Name
Neueste SEC-Einreichungen
Name
STOK's Discussions on Twitter

Vergleichen Sie STOK mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
STOK
Stoke Therapeutics Inc
14.27 740.88M 8.78M -104.70M -82.68M -2.37
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-18 Eingeleitet Jefferies Buy
2024-12-20 Eingeleitet Chardan Capital Markets Buy
2024-10-14 Fortgesetzt Leerink Partners Outperform
2024-03-26 Hochstufung TD Cowen Market Perform → Outperform
2023-11-20 Fortgesetzt JP Morgan Neutral
2023-07-25 Herabstufung TD Cowen Outperform → Market Perform
2023-05-01 Hochstufung BofA Securities Underperform → Neutral
2023-04-26 Fortgesetzt Canaccord Genuity Buy
2023-01-06 Herabstufung BofA Securities Buy → Underperform
2022-10-24 Hochstufung SVB Leerink Mkt Perform → Outperform
2022-01-31 Eingeleitet Jefferies Buy
2021-12-03 Eingeleitet BofA Securities Buy
2021-11-22 Hochstufung JP Morgan Neutral → Overweight
2021-05-18 Eingeleitet UBS Neutral
2021-05-10 Hochstufung Wedbush Neutral → Outperform
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-02-10 Herabstufung Wedbush Outperform → Neutral
2020-12-15 Fortgesetzt H.C. Wainwright Buy
2020-12-11 Bestätigt Needham Buy
2020-10-23 Eingeleitet Cantor Fitzgerald Overweight
2020-09-29 Fortgesetzt JP Morgan Neutral
2020-09-29 Eingeleitet Needham Buy
2019-12-18 Eingeleitet Wedbush Outperform
2019-11-12 Eingeleitet BTIG Research Buy
2019-10-25 Eingeleitet H.C. Wainwright Buy
2019-07-15 Eingeleitet Canaccord Genuity Buy
2019-07-15 Eingeleitet Cowen Outperform
2019-07-15 Eingeleitet Credit Suisse Outperform
2019-07-15 Eingeleitet JP Morgan Overweight
Alle ansehen

Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten

pulisher
Jul 23, 2025

Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

Stoke Therapeutics Bets Big On Rare Disease Therapies - Finimize

Jul 23, 2025
pulisher
Jul 23, 2025

Stoke Therapeutics Soars 17.02% on Market Optimism - AInvest

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Stoke Therapeutics Inc. stock priceRobust investment performance - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Stoke Therapeutics Inc. Stock Analysis and ForecastFree Investment Case Studies - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Stoke Therapeutics Inc. stockRapid growth opportunities - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Why Stoke Therapeutics Inc. stock attracts strong analyst attentionProven Return Strategy Execution - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

Published on: 2025-07-22 13:02:52 - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Is Stoke Therapeutics Inc. a good long term investmentExceptional profit velocity - PrintWeekIndia

Jul 21, 2025
pulisher
Jul 20, 2025

Jefferies Financial Group Begins Coverage on Stoke Therapeutics (NASDAQ:STOK) - Defense World

Jul 20, 2025
pulisher
Jul 20, 2025

How to Take Advantage of moves in (STOK) - news.stocktradersdaily.com

Jul 20, 2025
pulisher
Jul 19, 2025

Is Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - 富途牛牛

Jul 19, 2025
pulisher
Jul 19, 2025

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - simplywall.st

Jul 19, 2025
pulisher
Jul 19, 2025

Stoke Therapeutics (STOK): A High-Conviction Buy with Disease-Modifying Potential in Dravet Syndrome - AInvest

Jul 19, 2025
pulisher
Jul 18, 2025

Jefferies Recommends Stoke Therapeutics (STOK) with a Buy Rating - GuruFocus

Jul 18, 2025
pulisher
Jul 18, 2025

Jefferies initiates Stoke Therapeutics stock with Buy rating on epilepsy drug potential - Investing.com Canada

Jul 18, 2025
pulisher
Jul 18, 2025

Published on: 2025-07-18 11:35:29 - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 17, 2025

Stoke Therapeutics’ EMPEROR Study: A New Hope for Dravet Syndrome - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 16, 2025 - BioSpace

Jul 17, 2025
pulisher
Jul 16, 2025

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Stoke Therapeutics (STOK) - The Globe and Mail

Jul 16, 2025
pulisher
Jul 15, 2025

How Stoke Therapeutics Inc. stock performs during market volatilityProven Trading Plan - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Stoke Therapeutics Inc. stock price move sharplyDaily Price Surge List - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Stoke Therapeutics (NASDAQ:STOK) investors are sitting on a loss of 58% if they invested five years ago - Yahoo Finance

Jul 15, 2025

Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Kapitalisierung:     |  Volumen (24h):